Analysis of Interactions for Recombinant Protein Drugs and FcRn

Recombinant protein drugs are therapeutic protein drugs produced using DNA recombination technology or other biotechnologies. Compared to traditional low molecular synthetic drugs, they have the advantages of strong specificity, low toxicity, and significant therapeutic effects. However, as biological macromolecular drugs, recombinant protein drugs also have issues such as short half-life, easy degradation, low bioavailability, and low concentration at disease sites.

 

FcRn (Neonatal Fc Receptor) is a cell surface receptor molecule that binds to IgG and albumin in an acid-base dependent way, maintaining the concentration of IgG and albumin in the plasma and enabling their transmembrane transport. In addition, FcRn can also bind and promote the degradation of IgG-antigen complex multimers, enhancing the antigen presentation of antigen-presenting cells. FcRn is widely involved in various biological and immune processes in the body, playing roles in immune protection, maintaining the stability of IgG, transmembrane transport, and mother-infant transmission. Utilizing these characteristics of FcRn can help optimize the design of recombinant protein drugs, improving the stability, durability, efficacy, and safety of the drugs. Therefore, the interaction of recombinant protein drugs with FcRn is a key parameter to be optimized and tracked throughout the development process of recombinant protein drugs.

 

Surface Plasmon Resonance (SPR) technology can monitor the binding kinetics of recombinant protein with FcRn in real time, obtaining parameters such as binding affinity, binding constant, and dissociation constant, to evaluate the binding characteristics of the drug with FcRn. In addition, Immunoprecipitation (IP) technology can be used to form a complex of FcRn and drug recombinant protein by using a specific antibody to bind them, detecting the formation of the complex, and then using mass spectrometry to verify the formation of the complex and quantitatively analyze the interaction of the drug with FcRn.

 

MtoZ Biolabs provides professional services for the analysis of the interaction of recombinant protein drugs with FcRn. In addition, MtoZ Biolabs also provides various bio-product characterization services such as activity detection, structure characterization, charge heterogeneity characterization, and impurity analysis. We welcome detailed inquiries.